Amiodarone hepatotoxicity in the context of the metabolic syndrome and right-sided heart failure

Journal of Gastrointestinal and Liver Diseases

Volumn 18, Issue 4, 2009, Pages 419-423

  Mattar, Wissam ^a   Juliar, Beth ^b   Gradus Pizlo, Irmina ^b   Kwo, Paul Y ^b  

^a WASHINGTON HOSPITAL CENTER   (United States)

^b INDIANA UNIVERSITY   (United States)

Author keywords

Amiodarone; Congestive heart failure; Drug induced hepatitis; Liver; Metabolic syndrome

Indexed keywords

ALANINE AMINOTRANSFERASE; AMIODARONE; ASPARTATE AMINOTRANSFERASE; LIVER ENZYME;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CAUCASIAN; CLINICAL CHEMISTRY; COMMUNITY HOSPITAL; DISEASE ASSOCIATION; DISEASE COURSE; DOSE LIVER FUNCTION RELATION; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HEART DISEASE; HEART RIGHT VENTRICLE FAILURE; HUMAN; HYPERTRANSAMINASEMIA; LIVER DISEASE; LIVER EXAMINATION; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; METABOLIC SYNDROME X; PREVALENCE; THROMBOCYTE COUNT; TREATMENT DURATION;

ADULT; AGED; AGED, 80 AND OVER; ALANINE TRANSAMINASE; AMIODARONE; ANTI-ARRHYTHMIA AGENTS; ASPARTATE AMINOTRANSFERASES; BIOLOGICAL MARKERS; CLINICAL ENZYME TESTS; DRUG-INDUCED LIVER INJURY; FEMALE; HEART FAILURE; HUMANS; KAPLAN-MEIERS ESTIMATE; LINEAR MODELS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PREVALENCE; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; YOUNG ADULT;

EID: 74949105745     PISSN: 18418724     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Auer J, Berent R, Eber B. Amiodarone in the prevention and treatment of arrhythmia. Curr Opin Investig Drugs 2002; 3: 1037-1044.
2. Connolly SJ. Evidence-based analysis of amiodarone efficacy and safety. Circulation 1999; 100: 2025-2034.
3. Babatin M, Lee SS, Pollak PT. Amiodarone hepatotoxicity. Curr Vasc Pharmacol 2008; 6: 228-236.
4. Lewis JH, Ranard RC, Caruso A, et al. Amiodarone hepatotoxicity: prevalence and clinicopathologic correlations among 104 patients. Hepatology 1989; 9: 679-685.
5. McGovern B, Garan H, Kelly E, Ruskin JN. Adverse reactions during treatment with amiodarone hydrochloride. Br Med J (Clin Res Ed) 1983; 287: 175-180.
6. Harris L, McKenna WJ, Rowland E, Krikler DM. Side effects and possible contraindications of amiodarone use. Am Heart J 1983; 106: 916-923.
7. Kum LC, Chan WW, Hui HH, et al. Prevalence of amiodarone-related hepatotoxicity in 720 Chinese patients with or without baseline liver dysfunction. Clin Cardiol 2006; 29: 295-299.
8. Robinson K, Mulrow JP, Rowland E, McKenna WJ. Long-term effects of amiodarone on hepatic function. Am J Cardiol 1989; 64: 95-96.
9. Atiq M, Davis JC, Lamps LW, Beland SS, Rose JE. Amiodarone induced liver cirrhosis. Report of two cases. J Gastrointestin Liver Dis 2009; 18: 233-235.
10. Pollak PT, Shafer SL. Use of population modeling to define rational monitoring of amiodarone hepatic effects. Clin Pharmacol Ther 2004; 75: 342-351.
11. Pollak PT, You YD. Monitoring of hepatic function during amiodarone therapy. Am J Cardiol 2003; 91: 613-616.
12. Assy N, Kaita K, Mymin D, Levy C, Rosser B, Minuk G. Fatty infiltration of liver in hyperlipidemic patients. Dig Dis Sci 2000; 45: 1929-1934.
13. Knobler H, Schattner A, Zhornicki T, et al. Fatty liver - an additional and treatable feature of the insulin resistance syndrome. QJM 1999; 92: 73-79.
14. Marceau P, Biron S, Hould FS, et al. Liver pathology and the metabolic syndrome X in severe obesity. J Clin Endocrinol Metab 1999; 84: 1513-1517.
15. Lewis JH, Mullick F, Ishak KG, et al. Histopathologic analysis of suspected amiodarone hepatotoxicity. Hum Pathol 1990; 21: 59-67.
16. Geneve J, Zafrani ES, Dhumeaux D. Amiodarone-induced liver disease. J Hepatol 1989; 9: 130-133.
17. Guigui B, Perrot S, Berry JP, et al. Amiodarone-induced hepatic phospholipidosis: a morphological alteration independent of pseudoalcoholic liver disease. Hepatology 1988; 8: 1063-1068.
18. Kaufmann P, Torok M, Hanni A, Roberts P, Gasser R, Krahenbuhl S. Mechanisms of benzarone and benzbromarone-induced hepatic toxicity. Hepatology 2005; 41: 925-935.
19. Fromenty B, Fisch C, Labbe G, et al. Amiodarone inhibits the mitochondrial beta-oxidation of fatty acids and produces microvesicular steatosis of the liver in mice. J Pharmacol Exp Ther 1990; 255: 1371-1376.
20. Fromenty B, Fisch C, Berson A, Letteron P, Larrey D, Pessayre D. Dual effect of amiodarone on mitochondrial respiration. Initial protonophoric uncoupling effect followed by inhibition of the respiratory chain at the levels of complex I and complex II. J Pharmacol Exp Ther 1990; 255: 1377-1384.
21. Vorperian VR, Havighurst TC, Miller S, January CT. Adverse effects of low dose amiodarone: a meta-analysis. J Am Coll Cardiol 1997; 30: 791-798.
22. Pollak PT, Sharma AD, Carruthers SG. Relation of amiodarone hepatic and pulmonary toxicity to serum drug concentrations and superoxide dismutase activity. Am J Cardiol 1990; 65:1185-1191.
23. Tisdale JE, Follin SL, Ordelova A, Webb CR. Risk factors for the development of specific noncardiovascular adverse effects associated with amiodarone. J Clin Pharmacol 1995; 35: 351-356.
24. Rigas B, Rosenfeld LE, Barwick KW, et al. Amiodarone hepatotoxicity. A clinicopathologic study of five patients. Ann Intern Med 1986; 104: 348-351.
25. Shenasa M, Vaisman U, Wojciechowski M, Denker S, Murthy V, Akhtar M. Abnormal abdominal computerized tomography with amiodarone therapy and clinical significance. Am Heart J 1984; 107(5 Pt 1): 929-933.